Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus Infection
Open Access
- 1 March 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (3), 1339-1346
- https://doi.org/10.1128/aac.01803-12
Abstract
ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Here, to determine and analyze the correlation between the pharmacodynamic (PD) and pharmacokinetic (PK) parameters of ASP2151, we examined the PD profile of ASP2151 using in vitro plaque reduction assay and a murine model of HSV-1 infection. ASP2151 inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC 50 ) of 14 ng/ml. In the cutaneously HSV-1-infected mouse model, ASP2151 dose dependently suppressed intradermal HSV-1 growth, with the effect reaching a plateau at a dose of 30 mg/kg of body weight/day. The dose fractionation study showed that intradermal HSV-1 titers were below the detection limit in mice treated with ASP2151 at 100 mg/kg/day divided into two daily doses and at 30 or 100 mg/kg/day divided into three daily doses. The intradermal HSV-1 titer correlated with the maximum concentration of drug in serum ( C max ), the area under the concentration-time curve over 24 h (AUC 24h ), and the time during which the concentration of ASP2151 in plasma was above 100 ng/ml ( T >100 ). The continuous infusion of ASP2151 effectively decreased intradermal HSV-1 titers below the limit of detection in mice in which the ASP2151 concentration in plasma reached 79 to 145 ng/ml. Our findings suggest that the antiviral efficacy of ASP2151 is most closely associated with the PK parameter T >100 in HSV-1-infected mice. Based on these results, we propose that a plasma ASP2151 concentration exceeding 100 ng/ml for 21 to 24 h per day provides the maximum efficacy in HSV-1-infected mice.This publication has 35 references indexed in Scilit:
- Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, a Novel Helicase-Primase InhibitorAntimicrobial Agents and Chemotherapy, 2012
- ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding StudyThe Journal of Infectious Diseases, 2012
- Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital HerpesMolecules, 2011
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 HoursAntimicrobial Agents and Chemotherapy, 2003
- The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV‐infected childrenHIV Medicine, 2002
- A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpesJournal of Antimicrobial Chemotherapy, 1999
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Experimental herpes simplex virus type 1 (HSV‐1) infection of the spinal cord and dorsal root gangliaNeuropathology and Applied Neurobiology, 1995
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981